rentradВестник рентгенологии и радиологииJournal of radiology and nuclear medicine0042-46762619-0478Limited Liability Company "LUCHEVAYA DIAGNOSTIKA", Russian Association of Radiologists10.20862/0042-4676-2023-104-1-90-100rentrad-786Research ArticleОБЗОРЫREVIEWSВозможности магнитно-резонансной томографии в оценке эффективности фокального лечения рака предстательной железыMagnetic Resonance Imaging Evaluation of Focal Therapy Efficacy for Prostate Cancerhttps://orcid.org/0000-0001-6745-1672АбуладзеЛ. Р.AbuladzeL. R.

Абуладзе Лия Руслановна, мл. науч. сотр. сектора стандартизации и контроля качества отдела инновационных технологий; ординатор кафедры рентгенологии и  магнитно-резонансных исследований 

ул. Петровка, 24, стр. 1, Москва, 127051; ул. Большая Серпуховская, 27, Москва, 115093

Liya R. Abuladze, Junior Researcher, Standardization and Quality Control Sector, Department of Innovative Technologies; Resident Physician, Chair of Radiology and Magnetic Resonance Research 

ul. Petrovka, 24, str. 1, Moscow, 127051; ul. Bolshaya Serpukhovskaya, 27, Moscow, 115093

drliaabuladze@gmail.comhttps://orcid.org/0000-0003-3299-0574ГоворовА. В.GovorovA. V.

Говоров Александр Викторович, д. м. н., профессор кафедры урологии 

ул. Делегатская, 20, стр. 1, Москва, 127473

Alexander V. Govorov, Dr. Med. Sc., Professor, Chair of Urology 

ul. Delegatskaya, 20, str. 1, Moscow, 127473

https://orcid.org/0000-0002-5649-2193СиницынВ. Е.SinitsynV. E.

Синицын Валентин Евгеньевич, д. м. н., профессор, руководитель по развитию международного научного партнерства; заведующий кафедрой лучевой диагностики факультета фундаментальной медицины 

ул. Петровка, 24, стр. 1, Москва, 127051;Ленинские горы, 1, Москва, 119991

Valentin E. Sinitsyn, Dr. Med. Sc., Professor, Head for Development of International Scientific Partnership; Chief of Chair of Radiation Diagnostics, Faculty of Fundamental Medicine 

ul. Petrovka, 24, str. 1, Moscow, 127051; Leninskie Gory, 1, Moscow, 119991

ГБУЗ «Научно-практический клинический центр диагностики и телемедицинских технологий» Департамента здравоохранения г. Москвы; ФГБУ «Национальный медицинский исследовательский центр хирургии им. А.В. Вишневского» Минздрава РоссииРоссияResearch and Practical Clinical Center for Diagnostics and Telemedicine Technologies; Vishnevsky Nаtionаl Mediсаl Reseаrсh Сenter of SurgeryRussian FederationФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава РоссииРоссияYevdokimov Moscow State University of Medicine and DentistryRussian FederationГБУЗ «Научно-практический клинический центр диагностики и телемедицинских технологий» Департамента здравоохранения г. Москвы; ФГБОУ ВО «Московский государственный университет им. М.В. Ломоносова»РоссияResearch and Practical Clinical Center for Diagnostics and Telemedicine Technologies; Lomonosov Moscow State UniversityRussian Federation202301062023104190100Copyright © Абуладзе Л.Р., Говоров А.В., Синицын В.Е., 20232023Абуладзе Л.Р., Говоров А.В., Синицын В.Е.Abuladze L.R., Govorov A.V., Sinitsyn V.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.russianradiology.ru/jour/article/view/786

Рак предстательной железы (РПЖ) занимает второе место в структуре онкологической заболеваемости среди мужчин, причем частота встречаемости локализованных форм выше в странах с высоким уровнем дохода. На настоящий момент существует множество вариантов лечения локализованного РПЖ: начиная c тактики активного наблюдения и заканчивая методами фокальной терапии или радикальными подходами к лечению. С учетом того что многие пациенты заинтересованы в сохранении исходного уровня жизни и минимизации побочных эффектов, фокальная терапия представляет большой интерес не только для самих больных, но и для практикующих врачей-урологов. Магнитно-резонансная томография является одним из ведущих методов как первичной диагностики РПЖ, так и последующей оценки эффективности лечения, в т.ч. и после фокальной терапии. Мы предлагаем обобщенные данные анализа актуальной медицинской литературы по указанной теме.

Prostate cancer (PСa) is one of the leading causes of cancer morbidity in men. The incidence of localized PCa is higher in high-income countries. There are different types of treatment for localized PCa: from active surveillance to focal therapy or radical treatment. Both patients and urologists are interested in minimizing side effects of treatment, so focal therapy is an alternative option. Magnetic resonance imaging is one of the leading tools either for primary diagnosis or for following evaluation of treatment efficacy, including focal therapy. Therefore, we summarized literature data published on this topic.

рак предстательной железымагнитно-резонансная томографиясфокусированный ультразвук с высокой интенсивностьюкриотерапияфокальная лазерная аблациярадиочастотная аблациянеобратимая электропорацияфотодинамическая терапияфокальная брахитерапияprostate cancermagnetic resonance imaginghigh-intensity focused ultrasoundcryotherapyfocal laser ablationradiofrequency ablationirreversible electroporationphotodynamic therapyfocal brachytherapyReferencesFerlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5): E359–86. http://doi.org/10.1002/ijc.29210.Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5): E359–86. http://doi.org/10.1002/ijc.29210.Каприн А.Д., Старинский В.В., Шахзадова А.О. (ред.) Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). URL: https://glavonco.ru/cancer_register/Забол_2020_Электр.pdf (дата обращения 10.02.2023).Kaprin AD, Starinskiy VV, Shakhzadova AO (Eds). Malignant neoplasms in Russia in 2020 (morbidity and mortality). Available at: https://glavonco.ru/cancer_register/Забол_2020_Электр.pdf (in Russ.) (accessed February 10, 2023).Patel AR, Klein EA. Risk factors for prostate cancer. Nat Clin Pract Urol. 2009; 6(2): 87–95. http://doi.org/10.1038/ncpuro1290.Patel AR, Klein EA. Risk factors for prostate cancer. Nat Clin Pract Urol. 2009; 6(2): 87–95. http://doi.org/10.1038/ncpuro1290.Bleyer A, Spreafico F, Barr R. Prostate cancer in young men: an emerging young adult and older adolescent challenge. Cancer. 2020; 126(1): 46–57. http://doi.org/10.1002/cncr.32498.Bleyer A, Spreafico F, Barr R. Prostate cancer in young men: an emerging young adult and older adolescent challenge. Cancer. 2020; 126(1): 46–57. http://doi.org/10.1002/cncr.32498.Wang C, Zhang Y, Gao WQ. The evolving role of immune cells in prostate cancer. Cancer Lett. 2022; 525: 9–21. http://doi.org/10.1016/j.canlet.2021.10.027.Wang C, Zhang Y, Gao WQ. The evolving role of immune cells in prostate cancer. Cancer Lett. 2022; 525: 9–21. http://doi.org/10.1016/j.canlet.2021.10.027.Lowrance W, Breau R, Chou R, et al. AUA / ASTRO / SUO Guideline. Part I. J Urol. 2021; 205(1): 14–21. http://doi.org/10.1097/JU.0000000000001375.Lowrance W, Breau R, Chou R, et al. AUA / ASTRO / SUO Guideline. Part I. J Urol. 2021; 205(1): 14–21. http://doi.org/10.1097/JU.0000000000001375.Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. Cold Spring Harb Perspect Med. 2018; 8(12): a030361. http://doi.org/10.1101/cshperspect.a030361.Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. Cold Spring Harb Perspect Med. 2018; 8(12): a030361. http://doi.org/10.1101/cshperspect.a030361.Клинические рекомендации. Рак предстательной железы. 2021. URL: https://cr.minzdrav.gov.ru/recomend/12_3 (дата обращения 10.02.2023).Clinical guidelines. Prostate cancer. 2021. Available at: https://cr.minzdrav.gov.ru/recomend/12_3 (in Russ.) (accessed February 10, 2023).Borkowetz A, Blana A, Böhmer D, et al. German S3 evidencebased guidelines on focal therapy in localized prostate cancer: the first evidence-based guidelines on focal therapy. Urol Int. 2022; 106(5): 431–9. http://doi.org/10.1159/000521882.Borkowetz A, Blana A, Böhmer D, et al. German S3 evidencebased guidelines on focal therapy in localized prostate cancer: the first evidence-based guidelines on focal therapy. Urol Int. 2022; 106(5): 431–9. http://doi.org/10.1159/000521882.Hopstaken JS, Bomers JGR, Sedelaar MJP, et al. An updated systematic review on focal therapy in localized prostate cancer: what has changed over the past 5 years? Eur Urol. 2022; 81(1): 5–33. http://doi.org/10.1016/j.eururo.2021.08.005.Hopstaken JS, Bomers JGR, Sedelaar MJP, et al. An updated systematic review on focal therapy in localized prostate cancer: what has changed over the past 5 years? Eur Urol. 2022; 81(1): 5–33. http://doi.org/10.1016/j.eururo.2021.08.005.Turkbey B, Albert PS, Kurdziel K, Choyke PL. Imaging localized prostate cancer: current approaches and new developments. AJR Am J Roentgenol. 2009; 192(6): 1471–80. http://doi.org/10.2214/AJR.09.2527.Turkbey B, Albert PS, Kurdziel K, Choyke PL. Imaging localized prostate cancer: current approaches and new developments. AJR Am J Roentgenol. 2009; 192(6): 1471–80. http://doi.org/10.2214/AJR.09.2527.Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012. Eur Radiol. 2012; 22(4): 746–57. http://doi.org/10.1007/s00330-011-2377-y.Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012. Eur Radiol. 2012; 22(4): 746–57. http://doi.org/10.1007/s00330-011-2377-y.Park SY, Jung DC, Oh YT, et al. Prostate cancer: PI-RADS version 2 helps preoperatively predict clinically significant cancers. Radiology. 2016; 280(1): 108–16. http://doi.org/10.1148/radiol.16151133.Park SY, Jung DC, Oh YT, et al. Prostate cancer: PI-RADS version 2 helps preoperatively predict clinically significant cancers. Radiology. 2016; 280(1): 108–16. http://doi.org/10.1148/radiol.16151133.Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol. 2019; 76(3): 340–51. http://doi.org/10.1016/j.eururo.2019.02.033.Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol. 2019; 76(3): 340–51. http://doi.org/10.1016/j.eururo.2019.02.033.Callender T, Emberton M, Morris S, et al. Benefit, harm, and cost-effectiveness associated with magnetic resonance imaging before biopsy in age-based and risk-stratified screening for prostate cancer. JAMA Netw Open. 2021; 4: 1–12. https://doi.org/10.1001/jamanetworkopen.2020.37657.Callender T, Emberton M, Morris S, et al. Benefit, harm, and cost-effectiveness associated with magnetic resonance imaging before biopsy in age-based and risk-stratified screening for prostate cancer. JAMA Netw Open. 2021; 4: 1–12. https://doi.org/10.1001/jamanetworkopen.2020.37657.Tamada T, Kido A, Yamamoto A, et al. Comparison of biparametric and multiparametric MRI for clinically significant prostate cancer detection with PI-RADS version 2.1. J Magn Reson Imaging. 2021; 53: 283–91. https://doi.org/10.1002/jmri.27283.Tamada T, Kido A, Yamamoto A, et al. Comparison of biparametric and multiparametric MRI for clinically significant prostate cancer detection with PI-RADS version 2.1. J Magn Reson Imaging. 2021; 53: 283–91. https://doi.org/10.1002/jmri.27283.Абуладзе Л.Р., Семенов Д.С., Панина О.Ю., Васильев Ю.А. Оптимизированный протокол бипараметрической магнитно-резонансной томографии для диагностики рака предстательной железы. Digital Diagnostics. 2022: 3(3): 166–77. http://doi.org/10.17816/DD108484.Abuladze LR, Semenov DS, Panina OYu, Vasilev YuA. Optimized biparametric magnetic resonance imaging protocol for prostate cancer detection. Digital Diagnostics. 2022: 3(3): 166–77 (in Russ.). http://doi.org/10.17816/DD108484.Tay KJ, Scheltema MJ, Ahmed HU, et al. Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project. Prostate Cancer Prostatic Dis. 2017; 20(3): 294–9. http://doi.org/10.1038/pcan.2017.8.Tay KJ, Scheltema MJ, Ahmed HU, et al. Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project. Prostate Cancer Prostatic Dis. 2017; 20(3): 294–9. http://doi.org/10.1038/pcan.2017.8.Paxton M, Barbalat E, Perlis N, et al. Role of multiparametric MRI in long-term surveillance following focal laser ablation of prostate cancer. Br J Radiol. 2022; 95(1131): 20210414. http://doi.org/10.1259/bjr.20210414.Paxton M, Barbalat E, Perlis N, et al. Role of multiparametric MRI in long-term surveillance following focal laser ablation of prostate cancer. Br J Radiol. 2022; 95(1131): 20210414. http://doi.org/10.1259/bjr.20210414.Cordeiro ER, Cathelineau X, Thüroff S, et al. High-intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer. BJU Int. 2012; 110(9): 1228–42. http://doi.org/10.1111/j.1464-410X.2012.11262.x.Cordeiro ER, Cathelineau X, Thüroff S, et al. High-intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer. BJU Int. 2012; 110(9): 1228–42. http://doi.org/10.1111/j.1464-410X.2012.11262.x.Escoffre JM, Bouakaz A (Eds). Therapeutic ultrasound. Springer; 2016: 476 pp. http://doi.org/10.1007/978-3-319-22536-4.Escoffre JM, Bouakaz A (Eds). Therapeutic ultrasound. Springer; 2016: 476 pp. http://doi.org/10.1007/978-3-319-22536-4.Azzouz H, de la Rosette JJ. HIFU: local treatment of prostate cancer. EAU-EBU Updat Ser. 2006; 4: 62–70. https://doi.org/10.1016/j.eeus.2006.01.002.Azzouz H, de la Rosette JJ. HIFU: local treatment of prostate cancer. EAU-EBU Updat Ser. 2006; 4: 62–70. https://doi.org/10.1016/j.eeus.2006.01.002.He Y, Tan P, He M, et al. The primary treatment of prostate cancer with high-intensity focused ultrasound: a systematic review and meta-analysis. Medicine (Baltimore). 2020; 99(41): e22610. http://doi.org/10.1097/MD.0000000000022610.He Y, Tan P, He M, et al. The primary treatment of prostate cancer with high-intensity focused ultrasound: a systematic review and meta-analysis. Medicine (Baltimore). 2020; 99(41): e22610. http://doi.org/10.1097/MD.0000000000022610.Mearini L, Porena M. Transrectal high-intensity focused ultrasound for the treatment of prostate cancer: past, present, and future. Indian J Urol. 2010; 26(1): 4–11. http://doi.org/10.4103/0970-1591.60436.Mearini L, Porena M. Transrectal high-intensity focused ultrasound for the treatment of prostate cancer: past, present, and future. Indian J Urol. 2010; 26(1): 4–11. http://doi.org/10.4103/0970-1591.60436.Huber PM, Afzal N, Arya M, et al. Focal HIFU therapy for anterior compared to posterior prostate cancer lesions. World J Urol. 2021; 39(4): 1115–9. http://doi.org/10.1007/s00345-020-03297-7.Huber PM, Afzal N, Arya M, et al. Focal HIFU therapy for anterior compared to posterior prostate cancer lesions. World J Urol. 2021; 39(4): 1115–9. http://doi.org/10.1007/s00345-020-03297-7.Mearini L, D’Urso L, Collura D, et al. High-intensity focused ultrasound for the treatment of prostate cancer: a prospective trial with long-term follow-up. Scand J Urol. 2015; 49(4): 267–74. http://doi.org/10.3109/21681805.2014.988174.Mearini L, D’Urso L, Collura D, et al. High-intensity focused ultrasound for the treatment of prostate cancer: a prospective trial with long-term follow-up. Scand J Urol. 2015; 49(4): 267–74. http://doi.org/10.3109/21681805.2014.988174.Crouzet S, Chapelon JY, Rouvière O, et al. Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients. Eur Urol. 2014; 65(5): 907–14. http://doi.org/10.1016/j.eururo.2013.04.039.Crouzet S, Chapelon JY, Rouvière O, et al. Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients. Eur Urol. 2014; 65(5): 907–14. http://doi.org/10.1016/j.eururo.2013.04.039.Muller BG, Fütterer JJ, Gupta RT, et al. The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel. BJU Int. 2014; 113(2): 218–27. http://doi.org/10.1111/bju.12243.Muller BG, Fütterer JJ, Gupta RT, et al. The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel. BJU Int. 2014; 113(2): 218–27. http://doi.org/10.1111/bju.12243.Rouvière O, Lyonnet D, Raudrant A, et al. MRI appearance of prostate following transrectal HIFU ablation of localized cancer. Eur Urol. 2001; 40(3): 265–74. http://doi.org/10.1159/000049786.Rouvière O, Lyonnet D, Raudrant A, et al. MRI appearance of prostate following transrectal HIFU ablation of localized cancer. Eur Urol. 2001; 40(3): 265–74. http://doi.org/10.1159/000049786.Schaudinn A, Michaelis J, Franz T, et al. High-intensity focused ultrasound (HIFU) hemiablation of the prostate: late follow-up MRI findings in non-recurrent patients. Eur J Radiol. 2021; 144: 109957. http://doi.org/10.1016/j.ejrad.2021.109957.Schaudinn A, Michaelis J, Franz T, et al. High-intensity focused ultrasound (HIFU) hemiablation of the prostate: late follow-up MRI findings in non-recurrent patients. Eur J Radiol. 2021; 144: 109957. http://doi.org/10.1016/j.ejrad.2021.109957.Возможности магнитно-резонансной томографии в оценке состояния предстательной железы после проведенной HiFu терапии у больных раком предстательной железы. URL: https://uroweb.ru/article/vozmozhnosti-magnitnorezonansnoi-tomografii-v-otsenke-sostoyniya-predstatelnoizhelezy-posle-provedennoi-hifu-terapii (дата обращения 12.09.2022).The possibilities of magnetic resonance imaging in assessing the state of the prostate gland after HiFu therapy in patients with prostate cancer. Available at: https://uroweb.ru/article/vozmozhnosti-magnitno-rezonansnoi-tomografii-v-otsenkesostoyniya-predstatelnoi-zhelezy-posle-provedennoi-hifuterapii (in Russ.) (accessed September 12, 2022).Абоян И.А., Бадьян К.И., Маликов Л.Л. МРТ в диагностике рецидива рака предстательной железы после HIFU и криоабляции. В кн.: Сборник трудов XV конгресса «Мужское здоровье». Сочи; 2019.Aboyan IA, Badyan KI, Malikov LL. MRI in the diagnosis of prostate cancer recurrence after HIFU and cryoablation. In: Proceedings of the XV Congress “Men’s health”. Sochi; 2019 (in Russ.).Kim CK, Park BK, Lee HM, et al. MRI techniques for prediction of local tumor progression after high-intensity focused ultrasonic ablation of prostate cancer. AJR Am J Roentgenol. 2008; 190(5): 1180–6. http://doi.org/10.2214/AJR.07.2924.Kim CK, Park BK, Lee HM, et al. MRI techniques for prediction of local tumor progression after high-intensity focused ultrasonic ablation of prostate cancer. AJR Am J Roentgenol. 2008; 190(5): 1180–6. http://doi.org/10.2214/AJR.07.2924.Lotte R, Lafourcade A, Mozer P, et al. Multiparametric MRI for suspected recurrent prostate cancer after HIFU: is DCE still needed? Eur Radiol. 2018; 28(9): 3760–9. http://doi.org/10.1007/s00330-018-5352-z.Lotte R, Lafourcade A, Mozer P, et al. Multiparametric MRI for suspected recurrent prostate cancer after HIFU: is DCE still needed? Eur Radiol. 2018; 28(9): 3760–9. http://doi.org/10.1007/s00330-018-5352-z.Rosset R, Bratan F, Crouzet S, et al. Can pre- and postoperative magnetic resonance imaging predict recurrence-free survival after whole-gland high-intensity focused ablation for prostate cancer? Eur Radiol. 2017; 27(4): 1768–75. http://doi.org/10.1007/s00330-016-4491-3.Rosset R, Bratan F, Crouzet S, et al. Can pre- and postoperative magnetic resonance imaging predict recurrence-free survival after whole-gland high-intensity focused ablation for prostate cancer? Eur Radiol. 2017; 27(4): 1768–75. http://doi.org/10.1007/s00330-016-4491-3.Kirkham AP, Emberton M, Hoh IM, et al. MR imaging of prostate after treatment with high-intensity focused ultrasound. Radiology. 2008; 246(3): 833–44. http://doi.org/10.1148/radiol.2463062080.Kirkham AP, Emberton M, Hoh IM, et al. MR imaging of prostate after treatment with high-intensity focused ultrasound. Radiology. 2008; 246(3): 833–44. http://doi.org/10.1148/radiol.2463062080.Bui TL, Glavis-Bloom J, Chahine C, et al. Prostate minimally invasive procedures: complications and normal vs. abnormal findings on multiparametric magnetic resonance imaging (mpMRI). Abdom Radiol (NY). 2021; 46(9): 4388–400. http://doi.org/10.1007/s00261-021-03097-6.Bui TL, Glavis-Bloom J, Chahine C, et al. Prostate minimally invasive procedures: complications and normal vs. abnormal findings on multiparametric magnetic resonance imaging (mpMRI). Abdom Radiol (NY). 2021; 46(9): 4388–400. http://doi.org/10.1007/s00261-021-03097-6.Evans AJ. Treatment effects in prostate cancer. Mod Pathol. 2018; 31(1): 110–21. https://doi.org/10.1038/modpathol.2017.158.Evans AJ. Treatment effects in prostate cancer. Mod Pathol. 2018; 31(1): 110–21. https://doi.org/10.1038/modpathol.2017.158.Martino P, Scattoni V, Galosi AB, et al. Role of imaging and biopsy to assess local recurrence after definitive treatment for prostate carcinoma (surgery, radiotherapy, cryotherapy, HIFU). World J Urol. 2011; 29(5): 595–605. http://doi.org/10.1007/s00345-011-0687-y.Martino P, Scattoni V, Galosi AB, et al. Role of imaging and biopsy to assess local recurrence after definitive treatment for prostate carcinoma (surgery, radiotherapy, cryotherapy, HIFU). World J Urol. 2011; 29(5): 595–605. http://doi.org/10.1007/s00345-011-0687-y.Poissonnier L, Chapelon JY, Rouvière O, et al. Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol. 2007; 51(2): 381–7. http://doi.org/10.1016/j.eururo.2006.04.012.Poissonnier L, Chapelon JY, Rouvière O, et al. Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol. 2007; 51(2): 381–7. http://doi.org/10.1016/j.eururo.2006.04.012.Dickinson L, Ahmed HU, Hindley RG, et al. Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensity-focused ultrasound focal therapy for localized prostate cancer. Urol Oncol. 2017; 35(1): 30.e9–15. http://doi.org/10.1016/j.urolonc.2016.07.015.Dickinson L, Ahmed HU, Hindley RG, et al. Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensity-focused ultrasound focal therapy for localized prostate cancer. Urol Oncol. 2017; 35(1): 30.e9–15. http://doi.org/10.1016/j.urolonc.2016.07.015.Говоров А.В., Пушкарь Д.Ю., Васильев А.О. Криоаблация предстательной железы. Методические рекомендации № 20. 2015: 8–10.Govorov AV, Pushkar DYu, Vasiliev AO. Prostate cryoablation. Methodological recommendations No. 20. 2015: 8–10 (in Russ.).Guo RQ, Guo XX, Li YM, et al. Cryoablation, high-intensity focused ultrasound, irreversible electroporation, and vasculartargeted photodynamic therapy for prostate cancer: a systemic review and meta-analysis. Int J Clin Oncol. 2021; 26(3): 461–84. http://doi.org/10.1007/s10147-020-01847-y.Guo RQ, Guo XX, Li YM, et al. Cryoablation, high-intensity focused ultrasound, irreversible electroporation, and vasculartargeted photodynamic therapy for prostate cancer: a systemic review and meta-analysis. Int J Clin Oncol. 2021; 26(3): 461–84. http://doi.org/10.1007/s10147-020-01847-y.Говоров А.В., Васильев А.О., Пушкарь Д.Ю. Криохирургия рака предстательной железы. Consilium Medicum. 2015; 17(7): 29–32.Govorov AV, Vasiliev AO, Pushkar DY. Cryosurgery for prostate cancer. Consilium Medicum. 2015; 17(7): 29–32 (in Russ.).Sze C, Tsivian E, Tay KJ, et al. Anterior gland focal cryoablation: proof-of-concept primary prostate cancer treatment in select men with localized anterior cancers detected by multiparametric magnetic resonance imaging. BMC Urol. 2019; 19(1): 127. http://doi.org/10.1186/s12894-019-0562-5.Sze C, Tsivian E, Tay KJ, et al. Anterior gland focal cryoablation: proof-of-concept primary prostate cancer treatment in select men with localized anterior cancers detected by multiparametric magnetic resonance imaging. BMC Urol. 2019; 19(1): 127. http://doi.org/10.1186/s12894-019-0562-5.Overduin CG, Jenniskens SFM, Sedelaar JPM, et al. Percutaneous MR-guided focal cryoablation for recurrent prostate cancer following radiation therapy: retrospective analysis of iceball margins and outcomes. Eur Radiol. 2017; 27(11): 4828–36. http://doi.org/10.1007/s00330-017-4833-9.Overduin CG, Jenniskens SFM, Sedelaar JPM, et al. Percutaneous MR-guided focal cryoablation for recurrent prostate cancer following radiation therapy: retrospective analysis of iceball margins and outcomes. Eur Radiol. 2017; 27(11): 4828–36. http://doi.org/10.1007/s00330-017-4833-9.Patel P, Mathew MS, Trilisky I, Oto A. Multiparametric MR imaging of the prostate after treatment of prostate cancer. Radiographics. 2018; 38(2): 437–49. http://doi.org/10.1148/rg.2018170147.Patel P, Mathew MS, Trilisky I, Oto A. Multiparametric MR imaging of the prostate after treatment of prostate cancer. Radiographics. 2018; 38(2): 437–49. http://doi.org/10.1148/rg.2018170147.De Visschere PJ, De Meerleer GO, Fütterer JJ, Villeirs GM. Role of MRI in follow-up after focal therapy for prostate carcinoma. AJR Am J Roentgenol. 2010; 194(6): 1427–33. http://doi.org/10.2214/AJR.10.4263.De Visschere PJ, De Meerleer GO, Fütterer JJ, Villeirs GM. Role of MRI in follow-up after focal therapy for prostate carcinoma. AJR Am J Roentgenol. 2010; 194(6): 1427–33. http://doi.org/10.2214/AJR.10.4263.Kongnyuy M, Halpern DM, Liu CC, et al. 3-T multiparametric MRI characteristics of prostate cancer patients suspicious for biochemical recurrence after primary focal cryosurgery (hemiablation). Int Urol Nephrol. 2017; 49(11): 1947–54. http://doi.org/10.1007/s11255-017-1670-3.Kongnyuy M, Halpern DM, Liu CC, et al. 3-T multiparametric MRI characteristics of prostate cancer patients suspicious for biochemical recurrence after primary focal cryosurgery (hemiablation). Int Urol Nephrol. 2017; 49(11): 1947–54. http://doi.org/10.1007/s11255-017-1670-3.Hötker AM, Meier A, Mazaheri Y, et al. Temporal changes in MRI appearance of the prostate after focal ablation. Abdom Radiol (NY). 2019; 44(1): 272–8. http://doi.org/10.1007/s00261-018-1715-9.Hötker AM, Meier A, Mazaheri Y, et al. Temporal changes in MRI appearance of the prostate after focal ablation. Abdom Radiol (NY). 2019; 44(1): 272–8. http://doi.org/10.1007/s00261-018-1715-9.Rastinehad AR, Siegel DN, Wood BJ, McClure T (Eds). Interventional urology. Springer; 2022. http://doi.org/10.1007/978-3-030-73565-4.Rastinehad AR, Siegel DN, Wood BJ, McClure T (Eds). Interventional urology. Springer; 2022. http://doi.org/10.1007/978-3-030-73565-4.Chao B, Lepor H. 5-year outcomes following focal laser ablation of prostate cancer. Urology. 2021; 155: 124–9. http://doi.org/10.1016/j.urology.2021.03.054.Chao B, Lepor H. 5-year outcomes following focal laser ablation of prostate cancer. Urology. 2021; 155: 124–9. http://doi.org/10.1016/j.urology.2021.03.054.Walser E, Nance A, Ynalvez L, et al. Focal laser ablation of prostate cancer: results in 120 patients with low- to intermediate-risk disease. J Vasc Interv Radiol. 2019; 30(3): 401–9.e2. http://doi.org/10.1016/j.jvir.2018.09.016.Walser E, Nance A, Ynalvez L, et al. Focal laser ablation of prostate cancer: results in 120 patients with low- to intermediate-risk disease. J Vasc Interv Radiol. 2019; 30(3): 401–9.e2. http://doi.org/10.1016/j.jvir.2018.09.016.Westin C, Chatterjee A, Ku E, et al. MRI findings after MRI-guided focal laser ablation of prostate cancer. AJR Am J Roentgenol. 2018; 211(3): 595–604. http://doi.org/10.2214/AJR.17.19201.Westin C, Chatterjee A, Ku E, et al. MRI findings after MRI-guided focal laser ablation of prostate cancer. AJR Am J Roentgenol. 2018; 211(3): 595–604. http://doi.org/10.2214/AJR.17.19201.Koopman AG, Jenniskens SF, Fütterer JJ. Magnetic resonance imaging assessment after therapy in prostate cancer. Top Magn Reson Imaging. 2020; 29(1): 47–58. http://doi.org/10.1097/RMR.0000000000000231.Koopman AG, Jenniskens SF, Fütterer JJ. Magnetic resonance imaging assessment after therapy in prostate cancer. Top Magn Reson Imaging. 2020; 29(1): 47–58. http://doi.org/10.1097/RMR.0000000000000231.Felker ER, Raman SS, Lu DS, et al. Utility of multiparametric MRI for predicting residual clinically significant prostate cancer after focal laser ablation. AJR Am J Roentgenol. 2019; 213(6): 1253–8. http://doi.org/10.2214/AJR.19.21637.Felker ER, Raman SS, Lu DS, et al. Utility of multiparametric MRI for predicting residual clinically significant prostate cancer after focal laser ablation. AJR Am J Roentgenol. 2019; 213(6): 1253–8. http://doi.org/10.2214/AJR.19.21637.Osuchowski M, Bartusik-Aebisher D, Osuchowski F, Aebisher D. Photodynamic therapy for prostate cancer – a narrative review. Photodiagnosis Photodyn Ther. 2021; 33: 102158. http://doi.org/10.1016/j.pdpdt.2020.102158.Osuchowski M, Bartusik-Aebisher D, Osuchowski F, Aebisher D. Photodynamic therapy for prostate cancer – a narrative review. Photodiagnosis Photodyn Ther. 2021; 33: 102158. http://doi.org/10.1016/j.pdpdt.2020.102158.Trachtenberg J, Weersink RA, Davidson SR, et al. Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses. BJU Int. 2008; 102(5): 556–62. http://doi.org/10.1111/j.1464-410X.2008.07753.x.Trachtenberg J, Weersink RA, Davidson SR, et al. Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses. BJU Int. 2008; 102(5): 556–62. http://doi.org/10.1111/j.1464-410X.2008.07753.x.Azzouzi AR, Vincendeau S, Barret E, et al. Padeliporfin vasculartargeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. Lancet Oncol. 2017; 18(2): 181–91. http://doi.org/10.1016/S1470-2045(16)30661-1.Azzouzi AR, Vincendeau S, Barret E, et al. Padeliporfin vasculartargeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. Lancet Oncol. 2017; 18(2): 181–91. http://doi.org/10.1016/S1470-2045(16)30661-1.Kulik M, Nedelcu C, Martin F, et al. Post-treatment MRI aspects of photodynamic therapy for prostate cancer. Insights Imaging. 2014; 5(6): 697–713. http://doi.org/10.1007/s13244-014-0359-8.Kulik M, Nedelcu C, Martin F, et al. Post-treatment MRI aspects of photodynamic therapy for prostate cancer. Insights Imaging. 2014; 5(6): 697–713. http://doi.org/10.1007/s13244-014-0359-8.Ting F, Tran M, Böhm M, et al. Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control. Prostate Cancer Prostatic Dis. 2016; 19(1): 46–52. http://doi.org/10.1038/pcan.2015.47.Ting F, Tran M, Böhm M, et al. Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control. Prostate Cancer Prostatic Dis. 2016; 19(1): 46–52. http://doi.org/10.1038/pcan.2015.47.Guenther E, Klein N, Zapf S, et al. Prostate cancer treatment with irreversible electroporation (IRE): safety, efficacy and clinical experience in 471 treatments. PLoS One. 2019; 14(4): e0215093. http://doi.org/10.1371/journal.pone.0215093.Guenther E, Klein N, Zapf S, et al. Prostate cancer treatment with irreversible electroporation (IRE): safety, efficacy and clinical experience in 471 treatments. PLoS One. 2019; 14(4): e0215093. http://doi.org/10.1371/journal.pone.0215093.Blazevski A, Scheltema MJ, Yuen B, et al. Oncological and quality-of-life outcomes following focal irreversible electroporation as primary treatment for localised prostate cancer: a biopsy-monitored prospective cohort. Eur Urol Oncol. 2020; 3(3): 283–90. http://doi.org/10.1016/j.euo.2019.04.008.Blazevski A, Scheltema MJ, Yuen B, et al. Oncological and quality-of-life outcomes following focal irreversible electroporation as primary treatment for localised prostate cancer: a biopsy-monitored prospective cohort. Eur Urol Oncol. 2020; 3(3): 283–90. http://doi.org/10.1016/j.euo.2019.04.008.Scheltema MJ, Chang JI, van den Bos W, et al. Preliminary diagnostic accuracy of multiparametric magnetic resonance imaging to detect residual prostate cancer following focal therapy with irreversible electroporation. Eur Urol Focus. 2019; 5(4): 585–91. http://doi.org/10.1016/j.euf.2017.10.007.Scheltema MJ, Chang JI, van den Bos W, et al. Preliminary diagnostic accuracy of multiparametric magnetic resonance imaging to detect residual prostate cancer following focal therapy with irreversible electroporation. Eur Urol Focus. 2019; 5(4): 585–91. http://doi.org/10.1016/j.euf.2017.10.007.van den Bos W, de Bruin DM, van Randen A, et al. MRI and contrast-enhanced ultrasound imaging for evaluation of focal irreversible electroporation treatment: results from a phase I-II study in patients undergoing IRE followed by radical prostatectomy. Eur Radiol. 2016; 26(7): 2252–60. http://doi.org/10.1007/s00330-015-4042-3.van den Bos W, de Bruin DM, van Randen A, et al. MRI and contrast-enhanced ultrasound imaging for evaluation of focal irreversible electroporation treatment: results from a phase I-II study in patients undergoing IRE followed by radical prostatectomy. Eur Radiol. 2016; 26(7): 2252–60. http://doi.org/10.1007/s00330-015-4042-3.Wang H, Xue W, Yan W, et al. Extended focal ablation of localized prostate cancer with high-frequency irreversible electroporation: a nonrandomized controlled trial. JAMA Surg. 2022; 157(8): 693–700. http://doi.org/10.1001/jamasurg.2022.2230.Wang H, Xue W, Yan W, et al. Extended focal ablation of localized prostate cancer with high-frequency irreversible electroporation: a nonrandomized controlled trial. JAMA Surg. 2022; 157(8): 693–700. http://doi.org/10.1001/jamasurg.2022.2230.Aydin AM, Gage K, Dhillon J, et al. Focal bipolar radiofrequency ablation for localized prostate cancer: safety and feasibility. Int J Urol. 2020; 27(10): 882–9. http://doi.org/10.1111/iju.14321.Aydin AM, Gage K, Dhillon J, et al. Focal bipolar radiofrequency ablation for localized prostate cancer: safety and feasibility. Int J Urol. 2020; 27(10): 882–9. http://doi.org/10.1111/iju.14321.Feng C, Hu B, Hu B, et al. Comparative study of conventional US, contrast enhanced US and enhanced MR for the follow-up of prostatic radiofrequency ablation. Exp Ther Med. 2017; 13(6): 3535–42. http://doi.org/10.3892/etm.2017.4399.Feng C, Hu B, Hu B, et al. Comparative study of conventional US, contrast enhanced US and enhanced MR for the follow-up of prostatic radiofrequency ablation. Exp Ther Med. 2017; 13(6): 3535–42. http://doi.org/10.3892/etm.2017.4399.Zaorsky NG, Davis BJ, Nguyen PL, et al. The evolution of brachytherapy for prostate cancer. Nat Rev Urol. 2017; 14(7): 415–39. http://doi.org/10.1038/nrurol.2017.76.Zaorsky NG, Davis BJ, Nguyen PL, et al. The evolution of brachytherapy for prostate cancer. Nat Rev Urol. 2017; 14(7): 415–39. http://doi.org/10.1038/nrurol.2017.76.Matsuoka Y, Uehara S, Toda K, et al. Focal brachytherapy for localized prostate cancer: 5.7-year clinical outcomes and a pair-matched study with radical prostatectomy. Urol Oncol. 2022; 40(4): 161.e15–23. http://doi.org/10.1016/j.urolonc.2021.11.009.Matsuoka Y, Uehara S, Toda K, et al. Focal brachytherapy for localized prostate cancer: 5.7-year clinical outcomes and a pair-matched study with radical prostatectomy. Urol Oncol. 2022; 40(4): 161.e15–23. http://doi.org/10.1016/j.urolonc.2021.11.009.Valle LF, Greer MD, Shih JH, et al. Multiparametric MRI for the detection of local recurrence of prostate cancer in the setting of biochemical recurrence after low dose rate brachytherapy. Diagn Interv Radiol. 2018; 24(1): 46–53. http://doi.org/10.5152/dir.2018.17285.Valle LF, Greer MD, Shih JH, et al. Multiparametric MRI for the detection of local recurrence of prostate cancer in the setting of biochemical recurrence after low dose rate brachytherapy. Diagn Interv Radiol. 2018; 24(1): 46–53. http://doi.org/10.5152/dir.2018.17285.Tamada T, Sone T, Jo Y, et al. Locally recurrent prostate cancer after high-dose-rate brachytherapy: the value of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging in localizing tumors. AJR Am J Roentgenol. 2011; 197(2): 408–14. http://doi.org/10.2214/AJR.10.5772.Tamada T, Sone T, Jo Y, et al. Locally recurrent prostate cancer after high-dose-rate brachytherapy: the value of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging in localizing tumors. AJR Am J Roentgenol. 2011; 197(2): 408–14. http://doi.org/10.2214/AJR.10.5772.Panebianco V, Villeirs G, Weinreb JC, et al. Prostate magnetic resonance imaging for local recurrence reporting (PI-RR): international consensus -based guidelines on multiparametric magnetic resonance imaging for prostate cancer recurrence after radiation therapy and radical prostatectomy. Eur Urol Oncol. 2021; 4(6): 868–76. http://doi.org/10.1016/j.euo.2021.01.003.Panebianco V, Villeirs G, Weinreb JC, et al. Prostate magnetic resonance imaging for local recurrence reporting (PI-RR): international consensus -based guidelines on multiparametric magnetic resonance imaging for prostate cancer recurrence after radiation therapy and radical prostatectomy. Eur Urol Oncol. 2021; 4(6): 868–76. http://doi.org/10.1016/j.euo.2021.01.003.Gaur S, Turkbey B. Prostate MR imaging for posttreatment evaluation and recurrence. Urol Clin North Am. 2018; 45(3): 467–9. http://doi.org/10.1016/j.ucl.2018.03.011.Gaur S, Turkbey B. Prostate MR imaging for posttreatment evaluation and recurrence. Urol Clin North Am. 2018; 45(3): 467–9. http://doi.org/10.1016/j.ucl.2018.03.011.

The authors declare that there are no conflicts of interest present.